RxDoctor Payments Data

Arvind Mathur, MD

Internal Medicine · Hemet, CANPI 1962726471

Payments from drug & device makers

$350in general payments, 2019–2025

Across 18 payments — averaging $19.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$83
  • AbbVie$83
  • Sunovion Pharmaceuticals Inc.$39
  • Lundbeck LLC$32
  • Abbott$27
  • Shionogi Inc$22
  • plus $65 from 4 others

What the payments were for

  • Food & beverage$350100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$350 in reported general payments places this provider in the 60th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$394,560
Medicare patients
561
Services billed
3,421

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase96$759,400
Invega HafyeraPaliperidone Palmitate36$748,061
Invega TrinzaPaliperidone Palmitate33$336,176
EliquisApixaban602$249,943
OzempicSemaglutide70$65,417
LinzessLinaclotide42$60,409
XareltoRivaroxaban78$46,950
Xigduo XrDapaglifloz Propaned/Metformin27$46,922
JardianceEmpagliflozin112$45,422
RestasisCyclosporine23$44,619
FarxigaDapagliflozin Propanediol58$38,991
SynjardyEmpagliflozin/Metformin Hcl65$35,111
JanuviaSitagliptin Phosphate79$31,517
DescovyEmtricitabine/Tenofov Alafenam12$28,024
SantylCollagenase Clostridium Hist.15$25,708

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess, Restasis$83$864,429161 claims
MerckJanuvia$16$31,51779 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Hemet

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →